Soligenix, Inc. - Common Stock (SNGX)
Frequently Asked Questions About Soligenix, Inc. - Common Stock (SNGX)
How can investors learn more about Soligenix’s progress?
Investors can stay updated on Soligenix's progress by visiting the company’s official website, where they provide news releases, updated financial information, and resources related to their clinical trials and product development. Additionally, investors can follow the company through stock market platforms and financial news outlets for the latest announcements and developments.
How does Soligenix address patient needs?
Soligenix actively engages with patients, healthcare providers, and research collaborators to understand the specific needs and challenges associated with the medical conditions it aims to treat. By prioritizing patient input throughout the drug development process, the company strives to create therapies that effectively meet real-world demands and improve patient quality of life.
How does Soligenix approach clinical trials?
Soligenix, Inc. adopts a strategic and thorough approach to clinical trials, ensuring that its investigational drugs undergo rigorous testing for safety and efficacy. The company collaborates with clinical research organizations and utilizes experienced investigators to design and implement studies that meet regulatory standards, thereby optimizing the likelihood of successful outcomes.
How does Soligenix's funding strategy support its growth?
Soligenix employs a multifaceted funding strategy that includes raising capital through public offerings, securing grants, and exploring collaborations with larger pharmaceutical firms. This approach allows the company to finance its clinical trials and research initiatives while minimizing dilution of shareholder equity.
What are Soligenix's lead product candidates?
Soligenix's lead product candidates include SGX942, which is being developed for the treatment of oral mucositis in cancer patients, and SGX301, a topical therapy for cutaneous T-cell lymphoma. Both candidates are in advanced clinical stages, addressing significant unmet medical needs in their respective areas.
What are the company’s goals for the next few years?
In the coming years, Soligenix aims to advance its lead product candidates through clinical development, with a focus on achieving regulatory approvals and market entry. The company also seeks to expand its pipeline by exploring additional therapeutic areas and leveraging its innovative drug development platform.
What are the potential risks associated with investing in Soligenix?
As a clinical-stage biopharmaceutical company, investing in Soligenix poses several risks, including the uncertainty of clinical trial outcomes, potential regulatory hurdles, and market competition. Investors should consider these factors, as well as the company's financial stability and ability to execute its business plan, when evaluating potential investment.
What does Soligenix, Inc. do?
Soligenix, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing products to treat oral mucosal diseases, as well as other indications related to serious unmet medical needs. The company specializes in drug development for conditions such as cancer, inflammatory diseases, and rare diseases while utilizing innovative therapeutic platforms.
What is SGX301?
SGX301 is Soligenix's proprietary topical formulation for the treatment of cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. The candidate works by utilizing synthetic hypericin, which is activated by visible light to selectively target and destroy cancerous cells, thereby minimizing damage to surrounding healthy tissue.
What is SGX942?
SGX942 is a therapeutic candidate developed by Soligenix for the treatment of oral mucositis, a painful inflammation and ulceration of the mucous membranes in the mouth. The drug is designed to mitigate the side effects of cancer treatments, particularly in patients undergoing radiation or chemotherapy, by promoting healing and reducing pain.
What is Soligenix's commitment to research and development?
Soligenix is deeply committed to research and development (R&D) as a cornerstone of its business strategy. The company invests substantial resources into R&D efforts to foster innovation and discovery of new therapeutic solutions, ensuring that it remains at the forefront of biopharmaceutical advancements and effectively addresses medical needs.
What is the main therapeutic focus of Soligenix?
The main therapeutic focus of Soligenix, Inc. is on developing proprietary drugs for the treatment of serious conditions, particularly those affecting the oral mucosa and inflammatory diseases. Their leading candidates include therapies for rare diseases and advanced formulations that address the specific needs of patients with limited treatment options.
What is the market focus of Soligenix?
Soligenix targets markets with significant unmet medical needs, including oncology and rare diseases. The company focuses on developing therapies that not only improve patient outcomes but also address conditions lacking effective treatment options, which often leads to higher demand and market potential.
What is the significance of the company’s drug development platform?
Soligenix's drug development platform is significant because it combines advanced formulations and innovative therapeutic approaches that can address serious unmet medical needs. The platform supports the development of multiple product candidates across various indications, enhancing the company's potential for success in bringing new treatments to market.
What is the stock symbol for Soligenix, Inc.?
The stock symbol for Soligenix, Inc. is SNGX. It is publicly traded on the NASDAQ stock exchange, which provides greater visibility and access to capital for the company as it develops its innovative therapies.
What partnerships does Soligenix have?
Soligenix has formed several strategic partnerships with academic institutions and pharmaceutical companies to enhance its research capabilities and expedite the development of its product candidates. These collaborations leverage expertise and resources to overcome challenges in drug development and facilitate progress toward commercialization.
What recent achievements has Soligenix made?
Recently, Soligenix has achieved several milestones including advancements in its clinical trials for SGX942 and SGX301, and positive regulatory feedback from the FDA regarding its product candidates. The company has also successfully raised capital through public offerings, which supports its ongoing research and development efforts.
What role does the management team play at Soligenix?
The management team at Soligenix plays a crucial role in steering the company towards its goals. Comprising experienced professionals with extensive backgrounds in pharmaceutical development, clinical operations, and corporate strategy, the team provides expertise that guides decision-making, fosters innovation, and drives the company’s overall strategic direction.
Where is Soligenix, Inc. headquartered?
Soligenix, Inc. is headquartered in Princeton, New Jersey. This strategic location allows the company to be in close proximity to numerous leading pharmaceutical companies and research institutions, fostering opportunities for collaboration and partnership.
What is the current price of Soligenix, Inc. - Common Stock?
The current price of Soligenix, Inc. - Common Stock is 2.210
When was Soligenix, Inc. - Common Stock last traded?
The last trade of Soligenix, Inc. - Common Stock was at 4:00 pm EDT on April 2nd, 2025
What is the market capitalization of Soligenix, Inc. - Common Stock?
The market capitalization of Soligenix, Inc. - Common Stock is 6.97M
How many shares of Soligenix, Inc. - Common Stock are outstanding?
Soligenix, Inc. - Common Stock has 3.16M shares outstanding.